Skip to content

Cerebral small-vessel disease

TL;DR — Cerebral small-vessel disease (cSVD) is a spectrum of disorders affecting perforating arterioles, capillaries, and venules; MRI manifestations include recent small subcortical infarcts, lacunes, white-matter hyperintensities (WMH), perivascular spaces, microbleeds, superficial siderosis, and atrophy (Wardlaw 2013, PMID 23867200; Duering 2023, PMID 37236211). It causes lacunar ischemic stroke and deep intracerebral hemorrhage but also accumulates silently, disrupting distributed networks and contributing to slowed processing, executive dysfunction, gait impairment, falls, depression, apathy, urinary symptoms, and dementia (Cannistraro 2019, PMID 31142635; Markus 2023, PMID 36575578). Hypertension and age are dominant exposures, yet cSVD is not simply chronic ischemia: endothelial dysfunction, blood–brain barrier leakage, impaired vasoreactivity, vessel stiffening, altered fluid drainage, inflammation, demyelination, and secondary neurodegeneration interact (Wardlaw 2019, PMID 31097385). Blood-pressure control is the best-supported disease-modifying strategy; long-term aspirin–clopidogrel after lacunar stroke does not reduce recurrence and increases major bleeding and death (SPS3 Investigators 2012, PMID 22931315). Microbleeds predict intracranial hemorrhage during antithrombotic therapy but also mark ischemic risk, so their presence alone is not a treatment instruction (Wilson 2018, PMID 29778365; Best 2021, PMID 33743239).

What belongs under the cSVD umbrella

STRIVE standardized lesion definitions because inconsistent terms such as “leukoaraiosis,” “silent stroke,” and “small infarct” had made studies difficult to compare (Wardlaw 2013, PMID 23867200).

MRI feature STRIVE-compatible concept Typical interpretation Important mimic/pitfall
Recent small subcortical infarct Acute lesion in territory of one perforating arteriole Symptomatic lacunar infarction when clinic fits Embolic small infarct; branch atheromatous disease
Lacune Round/ovoid subcortical CSF cavity, usually 3–15 mm Healed small infarct or hemorrhage Enlarged perivascular space
WMH of presumed vascular origin T2/FLAIR hyperintensity, usually bilateral Cumulative white-matter injury Demyelination, edema, gliosis from other causes
Perivascular space Fluid-filled space along a penetrating vessel Marker of vessel/fluid-clearance milieu Tiny lacune; sequence/resolution dependence
Cerebral microbleed Small susceptibility signal from prior microscopic hemorrhage Hypertensive arteriopathy or CAA pattern Calcification, vessel flow void, artifact
Cortical superficial siderosis Linear cortical/subpial hemosiderin Strong hemorrhagic marker in CAA context Trauma, prior SAH, surgery
Brain atrophy Reduced tissue volume Downstream injury, aging, neurodegeneration Non-specific and segmentation-dependent

STRIVE-2 retains these core lesions while emphasizing lesion evolution, quantitative analysis, cortical microinfarcts, incidental diffusion lesions, network effects, and harmonized acquisition/reporting (Duering 2023, PMID 37236211).

The lesions are correlated but not interchangeable. A total cSVD score compresses burden for analysis, whereas lesion type and topography remain necessary for mechanism and treatment decisions.

Clinical phenotypes

Lacunar ischemic stroke

Classic lacunar syndromes include pure motor stroke, pure sensory stroke, sensorimotor stroke, ataxic hemiparesis, and dysarthria–clumsy hand syndrome. Clinical syndrome alone is imperfect: cortical embolic lesions and small hemorrhages can mimic a lacunar syndrome, while small subcortical infarcts can produce cognitive or atypical deficits.

Branch atheromatous disease proposes plaque at the parent artery or perforator origin producing a larger/deeper infarct and early progression. It is clinically useful but lacks a universally validated imaging/pathological boundary from intrinsic lipohyalinotic arteriolar disease (Petrone 2016, PMID 26671513).

Hemorrhagic cSVD

Deep hemispheric, basal-ganglia, thalamic, brainstem, and cerebellar microbleeds or hemorrhages often support hypertensive arteriopathy; strictly lobar microbleeds and cortical superficial siderosis support cerebral amyloid angiopathy (CAA). Mixed distributions are common and do not prove a single pathology (Greenberg 2009, PMID 19161908).

CAA is amyloid-β deposition in cortical and leptomeningeal vessel walls. Boston criteria v2.0 add non-hemorrhagic white-matter markers to hemorrhagic MRI features and were developed against neuropathology across a broader clinical spectrum, but remain probabilistic rather than histological diagnosis (Charidimou 2022, PMID 35841910).

Diffuse network syndrome

Accumulated cSVD can produce executive slowing, impaired attention, reduced processing speed, gait and balance dysfunction, falls, apathy, depression, and urinary urgency, sometimes without a recognized focal stroke (Cannistraro 2019, PMID 31142635; Markus 2023, PMID 36575578).

A 2023 systematic review/meta-analysis found worse gait and greater fall risk associated with multiple cSVD markers, including WMH, lacunes, microbleeds, and perivascular spaces; methods and gait outcomes were heterogeneous (Sharma 2023, PMID 37000039).

Longitudinal cohort meta-analysis also associates cSVD burden with incident depression, supporting a vascular-depression pathway while not proving that every late-life depressive syndrome is vascular (Fang 2020, PMID 32715831).

Mechanistic model

Process Human evidence Plausible tissue consequence Unresolved issue
Endothelial dysfunction Impaired vasoreactivity and circulating/vascular markers Dysregulated perfusion and barrier signaling Cause versus response to tissue injury
Blood–brain barrier leakage Dynamic-contrast MRI and tissue studies Plasma-protein exposure, edema, inflammation Spatial/temporal relation to new lesions
Arteriolar stiffening Pulsatility and vessel-wall remodeling Transmission of pressure into capillary bed Best modifiable surrogate
Impaired autoregulation Reduced response to perfusion demand Vulnerability during pressure variation Individual safe BP range
Drainage dysfunction Perivascular-space and interstitial-fluid hypotheses Metabolite/protein retention Direction of causality and measurement
Oligodendrocyte/myelin injury Diffusion and pathology changes beyond visible WMH Network disconnection Reversibility before cavitation
Inflammation Imaging, fluid, and pathology associations Endothelial activation and secondary injury Whether immune targeting changes clinical disease

The traditional chronic-hypoperfusion model is incomplete. Human observations support a dynamic “whole neurovascular unit” disorder with leakage, impaired vascular responses, altered interstitial-fluid handling, and secondary degeneration, but causal ordering is unresolved (Wardlaw 2013, PMID 23602162; Wardlaw 2019, PMID 31097385).

Normal-appearing white matter can be abnormal on diffusion, perfusion, and permeability imaging before visible WMH. This makes visible lesion volume an incomplete late-stage marker and a slow endpoint for early-phase trials (Duering 2023, PMID 37236211).

White-matter hyperintensities and covert infarcts

WMH are not benign incidental aging. A systematic review/meta-analysis of 46 longitudinal studies found high WMH burden associated with incident stroke (HR 3.3, 95% CI 2.6–4.4), dementia (HR 1.9, 95% CI 1.3–2.8), and death (HR 2.0, 95% CI 1.6–2.7) (Debette 2010, PMID 20660506).

A later meta-analysis across WMH, covert brain infarcts, microbleeds, and perivascular spaces confirmed that covert vascular brain injury predicts future stroke, dementia, and mortality, while effect magnitude differs by marker and study methods (Debette 2019, PMID 30422209).

MRI-defined silent brain infarction approximately doubled future symptomatic-stroke risk after adjustment (pooled HR 2.08, 95% CI 1.69–2.56), including in stroke-free population cohorts (Gupta 2016, PMID 26888534).

Marker What it predicts at group level What it does not establish
WMH volume/grade Stroke, dementia, death (PMID 20660506) That an individual lesion caused a symptom
Covert brain infarct Approximately doubled future stroke risk (PMID 26888534) Etiology without lesion pattern/workup
Microbleed Higher future ICH and ischemic-stroke risk Automatic contraindication to antithrombotic therapy (PMID 33743239)
Perivascular spaces Association with cSVD and clinical outcomes A validated treatment target by itself (PMID 30422209)

Cognition and dementia

Lacunar stroke is not cognitively “small.” A quantitative review of 17 studies found cognitive impairment across executive function, memory, language, attention, and visuospatial domains; impairment was not limited to executive tests (Edwards 2013, PMID 23319476).

cSVD can lower the threshold at which concomitant Alzheimer pathology becomes clinically expressed. Statistical adjustment for WMH does not cleanly separate vascular from neurodegenerative disease because the processes share age and vascular exposures and may interact (Wardlaw 2013, PMID 23867200).

Research-grade cognitive phenotyping should include processing speed/executive function, memory, language, visuospatial function, mood, gait, education, premorbid ability, and longitudinal recurrent lesions. Single screening-test cutoffs are inadequate for mechanism.

Microbleeds and antithrombotic decisions

Microbleed detection depends on field strength, echo time, spatial resolution, and susceptibility-weighted versus gradient-echo sequence. Counts from different protocols are not directly comparable (Greenberg 2009, PMID 19161908).

CROMIS-2 followed 1,447 anticoagulated patients with AF after ischemic stroke/TIA. Symptomatic intracranial hemorrhage occurred at 9.8 per 1,000 patient-years with microbleeds versus 2.6 without; adjusted HR 3.67 (95% CI 1.27–10.60). Adding microbleeds improved prediction beyond HAS-BLED, but absolute ischemic risk and wide intervals matter (Wilson 2018, PMID 29778365).

MICON pooled 15,766 patients on antithrombotic therapy from 38 cohorts and developed imaging-based scores for intracranial hemorrhage and ischemic stroke. Microbleed burden improved long-term risk prediction, but models require external calibration and do not substitute for the treatment-effect question (Best 2021, PMID 33743239).

RESTART imaging subgroup analyses did not find strong evidence that microbleeds or other cSVD features modified the effect of starting antiplatelet therapy after ICH, but subgroup confidence intervals were wide and cannot exclude clinically important heterogeneity (Al-Shahi Salman 2019, PMID 31129065).

Therefore microbleeds should change the precision of discussion, attention to blood pressure, and investigation of CAA—not trigger an unqualified “never anticoagulate” rule.

Prevention and treatment evidence

No therapy has yet shown that directly repairing the small-vessel endothelium prevents clinical cSVD. Management targets upstream vascular exposures and the mechanism of any symptomatic event.

SPS3 randomized 3,020 patients with MRI-defined lacunar stroke in a factorial design. Long-term clopidogrel added to aspirin did not reduce recurrent stroke (2.5% vs 2.7% per year; HR 0.92, 95% CI 0.72–1.16), nearly doubled major hemorrhage, and increased all-cause mortality (SPS3 Investigators 2012, PMID 22931315).

In the BP arm, achieved systolic pressure was 127 versus 138 mm Hg at one year for targets <130 versus 130–149 mm Hg. All recurrent stroke was nonsignificantly lower with the intensive target, while intracerebral hemorrhage was significantly reduced (HR 0.37, 95% CI 0.15–0.95) (SPS3 Study Group 2013, PMID 23726159).

SPRINT-MIND MRI was primary-prevention evidence in hypertensive adults without diabetes or prior stroke. Intensive systolic treatment (<120 vs <140 mm Hg) produced less WMH-volume increase over median 3.40 years (0.92 vs 1.45 cm³; between-group difference −0.54 cm³, 95% CI −0.87 to −0.20) but slightly greater total-brain-volume loss (Nasrallah 2019, PMID 31408137).

Strategy Evidence Bottom line
Sustained BP control SPS3; SPRINT-MIND Strongest modifiable strategy; exact target must consider symptoms and comorbidity (PMID 23726159; PMID 31408137)
Single antiplatelet after non-cardioembolic lacunar stroke Guideline-standard secondary prevention Use for symptomatic ischemic indication, not merely incidental WMH
Long-term aspirin + clopidogrel SPS3 No recurrence benefit; excess major bleeding/mortality (PMID 22931315)
Anticoagulation for documented AF AF treatment evidence plus microbleed risk stratification Microbleeds increase ICH risk but do not alone establish net harm (PMID 29778365)
Cognitive/gait rehabilitation Symptom-directed May improve function; not proven to halt lesion accumulation

Monogenic and other specific arteriopathies

Monogenic disease should be considered when onset is young, family history is strong, MRI distribution is characteristic, systemic features are present, or burden is disproportionate to conventional risk factors. Negative family history does not exclude de novo variants, recessive disease, limited family structure, or misdiagnosis.

Disorder/gene Clues Diagnostic caution
CADASIL / NOTCH3 Migraine with aura, subcortical strokes, psychiatric/cognitive features, anterior-temporal/external-capsule WMH Pathogenic variants typically alter cysteine residues; testing requires counseling and variant interpretation (Mosca 2011, PMID 21616505)
HTRA1-related disease / HTRA1 Recessive CARASIL or dominant later-onset cSVD; alopecia/spondylosis in classic recessive disease Phenotype and inheritance are broader than the historical CARASIL syndrome (Fukutake 2011, PMID 21301034; Whittaker 2022, PMID 35699195)
COL4A1/COL4A2-related angiopathy Porencephaly, hemorrhage, small-vessel lesions, ocular/renal/muscle features Expression is variable; review systemic phenotype (Whittaker 2022, PMID 35699195)
Fabry disease / GLA Neuropathic pain, angiokeratoma, renal/cardiac disease, posterior-circulation vascular features Unselected young-stroke screening estimates do not equal lacunar-cSVD prevalence
TREX1-related retinal vasculopathy Retinal vasculopathy plus tumefactive/white-matter lesions and systemic features Can mimic inflammatory, neoplastic, or sporadic cSVD (Whittaker 2022, PMID 35699195)

In an MRI-defined younger-onset lacunar-stroke cohort, pathogenic CADASIL and Fabry diagnoses were uncommon, illustrating why clinical and imaging enrichment is preferable to assuming every young lacunar stroke is monogenic (Kilarski 2015, PMID 26305465).

A systematic review catalogued overlapping cerebral phenotypes across monogenic cSVD genes and emphasized that clinical presentation alone often cannot identify the gene; standardized phenotyping and variant adjudication are required (Whittaker 2022, PMID 35699195).

Measurement problems in cSVD trials

Problem Consequence Better practice
Scanner/sequence change Apparent lesion progression or microbleed “incidence” Harmonized protocol and centralized quality control (PMID 37236211)
Dichotomous Fazekas grade Information loss and ceiling effects Continuous lesion volume plus location and uncertainty
Visible lesions only Misses abnormal normal-appearing tissue Add diffusion/perfusion/permeability or network measures where justified
Cross-sectional cognition Reverse causation and premorbid confounding Longitudinal domain battery with recurrent-lesion surveillance
Composite cSVD score Equal weighting of biologically different lesions Report components alongside composite
Short follow-up Few clinical events and slow WMH change Efficient validated surrogate plus long clinical follow-up

The field needs biomarkers that are sensitive to change, reproducible across scanners, mechanistically proximal, and demonstrably predictive of outcomes that matter. An association with cSVD is not enough for surrogate validation (Duering 2023, PMID 37236211).

Open questions

  • Does blood–brain barrier leakage precede and cause new WMH/lacunes, or reflect already injured tissue (Wardlaw 2019, PMID 31097385)?
  • What blood-pressure range minimizes both cumulative cSVD injury and hypoperfusion symptoms in patients with impaired autoregulation (SPS3 Study Group 2013, PMID 23726159)?
  • Can quantitative diffusion or permeability markers serve as validated early endpoints before visible lesion progression (Duering 2023, PMID 37236211)?
  • Which combination of microbleed number, distribution, superficial siderosis, genotype, and BP identifies net benefit from anticoagulation rather than hemorrhage risk alone (Wilson 2018, PMID 29778365; Best 2021, PMID 33743239)?
  • Are gait, mood, and cognitive phenotypes driven by shared network disconnection, and can one intervention improve all three (Sharma 2023, PMID 37000039; Fang 2020, PMID 32715831)?
  • Which apparently sporadic early-onset cases warrant broad sequencing rather than targeted NOTCH3 testing (Whittaker 2022, PMID 35699195)?

References

  1. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822-838. PMID 23867200
  2. Duering M, Biessels GJ, Brodtmann A, et al. Neuroimaging standards for research into small vessel disease—advances since 2013. Lancet Neurol. 2023;22:602-618. PMID 37236211
  3. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019;18:684-696. PMID 31097385
  4. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol. 2013;12:483-497. PMID 23602162
  5. Cannistraro RJ, Badi M, Eidelman BH, et al. CNS small vessel disease: a clinical review. Neurology. 2019;92:1146-1156. PMID 31142635
  6. Markus HS, de Leeuw FE. Cerebral small vessel disease: recent advances and future directions. Int J Stroke. 2023;18:4-14. PMID 36575578
  7. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain MRI: systematic review and meta-analysis. BMJ. 2010;341:c3666. PMID 20660506
  8. Debette S, Schilling S, Duperron MG, et al. Clinical significance of MRI markers of vascular brain injury: systematic review and meta-analysis. JAMA Neurol. 2019;76:81-94. PMID 30422209
  9. Gupta A, Giambrone AE, Gialdini G, et al. Silent brain infarction and risk of future stroke: systematic review and meta-analysis. Stroke. 2016;47:719-725. PMID 26888534
  10. Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009;8:165-174. PMID 19161908
  11. Wilson D, Ambler G, Shakeshaft C, et al. Cerebral microbleeds and intracranial haemorrhage risk in anticoagulated patients after ischemic stroke/TIA: CROMIS-2. Lancet Neurol. 2018;17:539-547. PMID 29778365
  12. Best JG, Ambler G, Wilson D, et al. Imaging-based risk scores for intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy: MICON. Lancet Neurol. 2021;20:294-303. PMID 33743239
  13. Charidimou A, Boulouis G, Frosch MP, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy. Lancet Neurol. 2022;21:714-725. PMID 35841910
  14. SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367:817-825. PMID 22931315
  15. SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke. Lancet. 2013;382:507-515. PMID 23726159
  16. Nasrallah IM, Pajewski NM, Auchus AP, et al. Association of intensive vs standard blood pressure control with cerebral white matter lesions. JAMA. 2019;322:524-534. PMID 31408137
  17. Al-Shahi Salman R, Minks DP, Mitra D, et al. Effects of antiplatelet therapy on stroke risk by brain imaging features of ICH and cSVD: RESTART subgroup analyses. Lancet Neurol. 2019;18:643-652. PMID 31129065
  18. Edwards JD, Jacova C, Sepehry AA, et al. A quantitative systematic review of domain-specific cognitive impairment in lacunar stroke. Neurology. 2013;80:315-322. PMID 23319476
  19. Sharma B, et al. Gait and falls in cerebral small vessel disease: a systematic review and meta-analysis. Age Ageing. 2023;52:afad011. PMID 37000039
  20. Fang Y, Qin T, Liu W, et al. Cerebral small-vessel disease and risk of incident depression: a meta-analysis of longitudinal cohort studies. J Am Heart Assoc. 2020;9:e016512. PMID 32715831
  21. Petrone L, Nannoni S, Del Bene A, et al. Branch atheromatous disease: a clinically meaningful, yet unproven concept. Cerebrovasc Dis. 2016;41:87-95. PMID 26671513
  22. Mosca L, Marazzi R, Ciccone A, et al. NOTCH3 gene mutations in subjects clinically suspected of CADASIL. J Neurol Sci. 2011;307:144-148. PMID 21616505
  23. Fukutake T. CARASIL. Brain Nerve. 2011;63:99-108. PMID 21301034
  24. Whittaker E, Thrippleton S, Chong LYW, et al. Systematic review of cerebral phenotypes associated with monogenic cerebral small-vessel disease. J Am Heart Assoc. 2022;11:e025629. PMID 35699195
  25. Kilarski LL, Rutten-Jacobs LCA, Bevan S, et al. Prevalence of CADASIL and Fabry disease in MRI-defined younger-onset lacunar stroke. PLoS One. 2015;10:e0136352. PMID 26305465